menu ☰
menu ˟

Third phase 3 trial shows HEPLISAV-B vaccine safe, effective against HBV

20 Apr 2016
BALTIMORE — Results from the HBV-23 phase 3 trial show that the investigational hepatitis B vaccine HEPLISAV-B provided statistically significant higher rates of protection with fewer doses than a currently licensed vaccine with a similar safety pr...

Click here to view the full article which appeared in Nursing

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.